Day: September 7, 2022

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Acceptance Test Procedures (ATP) for the first Protector RG Mk1 Remotely Piloted Aircraft (RPA) system was completed on Aug. 26, 2022. Completion of ATP allows for the official hand-over of the aircraft to the UK Royal Air Force (RAF), the launch customer of the MQ-9B RPA system developed by General Atomics Aeronautical Systems, Inc. (GA-ASI). Protector is a specially configured model of MQ-9B, designed to meet the unique requirements of the RAF.

The International City/County Management Association has adopted a new global engagement strategy to assure their future as the premier resource for local government professionals across the globe

WASHINGTON, Sept. 07, 2022 (GLOBE NEWSWIRE) — The International City/County Management Association (ICMA), announced a new initiative aimed at strengthening local government management practices through a global learning approach. In collaboration with its partners and members throughout the world, ICMA will develop new programs, launch new services, and conduct new research in order to advance effective local government management practices.

“No matter where you are in the world, and regardless of the form of government a nation adopts, local government officials are the ones who have the most direct impact on our daily lives,” said Marc Ott, ICMA executive director and CEO. “This new initiative adopted by our board provides strategic direction as we continue to serve as the leading voice on local government management and administration practices.”

ICMA has a long history of supporting local governments across the globe. Through federal grant programs and partnerships, ICMA has advanced essential thought leadership on issues such as pollution mitigation, financial and economic stability, education, and urban planning in over 70 countries since its founding. Through existing programs, ICMA has already enabled 3,000 individuals in the Philippines to utilize climate information to improve resiliency and provided 60 youth in Bangladesh with mentorship to develop conflict-management and other skills.

These international collaborations are the catalyst for this new global strategy, which will support further strategic commitment to sharing ICMA’s resources and expertise with local governments around the world.

“In an ever more globalized world, we have so much to learn from each other as we strive to serve our communities,” said Troy Brown, President of ICMA. “We’re excited to see the types of thought leadership and new ideas that emerge from a more direct international emphasis on government administration across the globe.”

In our increasingly globalized society, many of the most pressing, complex issues facing local governments, from climate change to public health, transcend borders. There are over 500,000 local governments around the globe that employ millions of individuals, representing a significant opportunity to share ICMA’s educational opportunities and expertise.

About ICMA
The International City/County Management Association (ICMA), advances professional local government management worldwide through leadership, management, innovation, and ethics. ICMA provides member support; publications; data and information; peer and results-oriented assistance; and training and professional development to more than 12,000 city, town, and county experts and other individuals and organizations throughout the world. The management decisions made by ICMA’s members affect millions of individuals living in thousands of communities, from small villages and towns to large metropolitan areas. ICMA has gathered more data on local government than any organization except the federal government, spanning a broad spectrum from economic development to local government innovation.

Media contact:

Marykate Cary Mattiello

mcary@groupgordon.com

212-784-5708

Crane trained with AI technology performs automated point-to-point operation while suppressing the load sway.

TOKYO, Sept. 07, 2022 (GLOBE NEWSWIRE) — DeepX, Inc. (Headquarters: Bunkyo-ku, Tokyo, CEO: Kaoru Nasuno, hereinafter DeepX) and Tadano Ltd. (Headquarters: Takamatsu City, Kagawa Prefecture, President: Toshiaki Ujiie, hereinafter Tadano) have released the progress of a joint research project of crane automation utilizing AI technology.

Introduction movie of DeepX’s crane automation project can be found here: https://youtu.be/MHR4vxtgCCU

Background and purpose of this project

Cranes are general-purpose lifting equipment widely used in construction industries. Crane operators must operate multiple levers simultaneously while checking the position of the load visually. In addition, cranes are affected by the boom deflection and wind, so it takes a long time to become a proficient crane operator. On the other hand, the number of skilled crane operators in Japan is declining due to the aging population. The aim of this joint R&D project is to improve safety at work sites by simplifying and automating mobile crane operations by utilizing AI technologies.

Crane automation and its technical approach

Mobile cranes are known to be one of the most difficult machines to operate on construction sites.  Slewing and elevating motion in mobile cranes typically generates undesirable two-dimensional load-sway; therefore, crane operators must be highly skilled to suppress this sway upon completion of the point-to-point crane maneuver. DeepX and Tadano have therefore developed a control algorithm based on AI technology, levaredging simulator environment for controller optimization. Using this algorithm, the operator can safely and accurately move the load to the desired position while suppressing load sway.

Future prospects

DeepX will continue to work with Tadano to challenge more complex operations and further advance the technology for mobile crane automation. DeepX will also aim to apply this technology to various types of cranes in a wide range of industries.

About DeepX

DeepX is an AI startup that has its roots in the Matsuo Laboratory at the University of Tokyo with the mission of “Automating Any Machine and Innovating Global Industries”. By automating any kind of machine and promoting the automation of a wide range of manual work using various technologies including AI, DeepX aims to solve problems such as labor and skilled worker shortages as well as excessive staff workloads, which are significant challenges to many industries.

Established:  April 22, 2016

Business: Support for automation of machinery and field operations, business development using AI technology, software development, and R&D

URL: https://www.deepx.co.jp/

About the Tadano Group

Since Tadano developed Japan’s first hydraulic truck crane in 1955, the company has grown globally, while constantly striving to implement our Corporate Philosophy of Creation, Contribution, and Cooperation. The Tadano Group delivers our Core Values – Safety, Quality, and Efficiency Based on Compliance (C+SQE) – in each and every one of our products and services.

URL: https://www.tadano.com/

Contact

info@deepx.co.jp

Related Images

Image 1: Mobile crane

Crane used in this project and its simulation environment

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Mobile crane

Neovii and Fosun Pharma Enter into an Exclusive Agreement for Development and Commercialization for Grafalon in China

ST. GALLEN, Switzerland, Sept. 07, 2022 (GLOBE NEWSWIRE) — Neovii Pharmaceuticals AG (“Neovii”), a Swiss based global specialty-care biopharmaceutical company, and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd (“Fosun Pharma Industry”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, Stock Code: 600196.SH, 02196.HK), a global pharmaceutical and healthcare industry group deep-rooted in China, have entered into an exclusive agreement (the “Agreement”), under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii’s Grafalon® (rabbit anti-human T-lymphocyte globulin, ATLG) in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon® to Fosun Pharma Industry.

The parties’ aim is to firstly strengthen Grafalon’s position in the field of transplantation medicine in China, in which it is already approved for marketing and included in China’s National Reimbursement Drug List. Further, the Agreement entails clinical development to expand Grafalon’s regulatory approval in China to the prevention of Graft versus Host Disease following allogenic stem cell transplantation (“SCT”), so as to align its approved usages in China with those in Europe and other countries worldwide. Additional objective is to evolve Grafalon’s usages from transplantation medicine to auto-immune and onco-hematology conditions, where Grafalon has the potential to positively-transform the lives of patients suffering from severe diseases with high unmet need. The Agreement also sets the foundation to expand the cooperation to additional products of Neovii, starting from NB-15, a novel, clinical-stage therapy that is under development for the treatment of Mitochondrial neurogastrointestinal encephalomyo-pathy (MNGIE), an ultra-rare, devastating and uniformly fatal disorder.

Wen Deyong, CEO of Fosun Pharma said: “Grafalon has an excellent effect in solid organ transplant recipients, especially those with a high risk of rejection. We are very pleased to be working with Neovii to bring this product into China. Going forward, we will leverage our advantages in nephrology and hematology and more areas to make the medicines accessible to patients and benefiting more Chinese patients.”

Dr. Christian Loss, CEO of Neovii said: “As a leading global pharmaceutical and healthcare industry group in China, Fosun Pharma is the ideal partner to develop and commercialize Grafalon in China. This collaboration positions Grafalon for sustained growth in China and advances the development in stem cell transplant and beyond as in devastating auto-immune and other diseases. We look forward to working with Fosun Pharma to bring Grafalon to more patients in-need in China.”

Neovii was supported by Marshal Ma of Link China Pharma Solutions (Cambridge, UK based), who gave valuable help in the negotiation process.

About Grafalon
Grafalon® (Rabbit anti-human T-lymphocyte globulin, ATLG, formerly also known as “ATG-Fresenius S” and “ATG-F”) was developed by Neovii and is used to improve patients’ outcomes in transplantation medicine in more than 50 countries and, in selected countries, also to treat aplastic anemia. With more than 250,000 treated patients, 30 years of clinical experience and leadership position in many countries, Grafalon® has transformed the way transplant teams manage the care of their patients and is uniquely addressing significant unmet needs. The authorized use for each country varies based on the design of the registrational trial and the individual health authority requirements. For more details, please refer to the approved product information for each respective jurisdiction.

About Neovii
Neovii is a Swiss-based, global, fully integrated, rapidly-growing, commercial-stage, specialty-care biopharmaceutical company with sales in more than 50 countries. Neovii has a proven track-record of over more than three decades in pursuing its mission to bring novel life-transforming therapies to patients that suffer from devastating conditions with significant unmet medical needs. Neovii is a member of the Neopharm Group that, through its family of companies, is engaged in research, development and commercialization of a broad range of products and added-value services in three major segments: Pharmaceutical, Medical and Consumer Healthcare, with revenues exceeding $500 million and more than 1,000 employees worldwide.

Cautionary Note on Forward-Looking Statements
This press release, the statements herein or those of representatives and partners of Neovii related thereto contain, or may contain, among other things, certain “forward-looking statements”. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Neovii’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the current beliefs and expectations of Neovii’s management and are subject to significant risks and uncertainties. Actual results (including, without limitation, those relating to the SCT approval in China) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Neovii’s control). Neovii undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For more information, please visit www.neovii.com
Neovii Pharmaceuticals AG
Zürcherstrasse 19
8640 Rapperswil
Switzerland
Tel: +41 55 210 05 00
Email: belen.podesta@neovii.com

About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth”, with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

For more information, please visit Fosun’s official website: www.fosunpharma.com.

Related Images

1: Neovii and Fosun Logo

Neovii and Fosun Logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Neovii and Fosun Logo